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A B S T R A C T
Background
In the treatment of urothelial carcinoma of the bladder, we are currently uncertain of the benefits and harms of standard pelvic lymph
node dissection (PLND) compared to extended PLND.
Objectives
To assess the effects of extended versus standard PLND in patients undergoing cystectomy to treat muscle-invasive (cT2 and cT3) and
treatment-refractory, non-muscle-invasive (cT1 with or without carcinoma in situ) urothelial carcinoma of the bladder.
Search methods
We performed a comprehensive literature search using multiple databases (PubMed, Embase, Cochrane Controlled Trials, Web of
Science, and LILACS), trial registries, and conference proceedings published up to April 29, 2019, with no restrictions on the language
or status of publication.
Selection criteria
We included randomized controlled trials in which participants underwent radical cystectomy (RC) for muscle-invasive or therapy-
refractory non-muscle-invasive urothelial carcinoma of the bladder with either an extended PLND with a superior extent reaching as
far cranially as the inferior mesenteric vein, or a standard PLND with a superior extent of the bifurcation of the internal and external
iliac artery, with otherwise the same anatomical boundaries.
Data collection and analysis
Two review authors independently assessed the included studies and extracted data from them for the primary outcomes: time to death
from any cause, time to death from bladder cancer and Clavien-Dindo classification of surgical complications grade III-V, and the
secondary outcomes: time to recurrence, Clavien-Dindo I-II complications and disease-specific quality of life.
We performed statistical analyses using a random-effects model and rated the certainty of evidence according to the GRADE approach.
1Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The search identified one multicenter trial based in Germany that enrolled 401 participants with histologically confirmed T1 grade 3
or muscle-invasive urothelial carcinoma. The median age was 67 years (range: 59 to 74) and the majority of participants were male
(78.3%). No participant received neoadjuvant chemotherapy; a small subset received adjuvant chemotherapy (14.5%).
Primary outcomes
Our results indicate that extended PLND may reduce the risk of death from any cause over time as compared to standard PLND,
but the confidence interval includes the possibility of no effect (hazard ratio [HR]: 0.78, 95% confidence interval [CI]: 0.57 to 1.07,
401 participants, low-certainty evidence). After five years of follow-up, this may result in 83 fewer deaths (95% CI: 174 fewer to 24
more overall deaths) per 1000 participants: 420 deaths for extended PLND compared to 503 deaths per 1000 for standard PLND. We
downgraded the certainty of evidence by two levels due to study limitations and imprecision.
Our results indicate that extended PLND may reduce the risk of death from bladder cancer over time as compared to standard PLND
but, again, the confidence interval includes the possibility of no effect (HR: 0.70, 95% CI: 0.45 to 1.07, participants = 401, low-
certainty evidence). After five years of follow-up, this corresponds to 91 fewer deaths per 1000 participants (95% CI: 176 fewer to 19
more bladder cancer deaths): 264 deaths for extended PLND compared to 355 deaths per 1000 for standard PLND. We downgraded
the certainty of evidence by two levels due to study limitations and imprecision.
Based on follow-up of up to 30 days, we are uncertain whether extended PLND leads to more grade III-V complications as compared
to standard PLND, because of study limitations and imprecision (risk ratio [RR]: 1.13, 95% CI: 0.84 to 1.52, participants = 401, very
low-certainty evidence).
Secondary outcomes
We are uncertain whether extended PLND reduces the risk of recurrence over time as compared to standard PLND, because of study
limitations and imprecision (HR: 0.84, 95% CI: 0.58 to 1.22, participants = 401, very low-certainty evidence).
Based on follow-up of up to 30 days, we are uncertain whether extended PLND leads to similar grade I-II complications as compared to
standard PLND because of study limitations and imprecision (RR: 0.94, 95% CI: 0.74 to 1.19, participants = 401, very low-certainty
evidence).
We found no trials that reported on disease-specific quality of life.
Authors’ conclusions
Results from a single trial indicate that extended PLND in patients undergoing radical cystectomy for invasive urothelial carcinoma
of the bladder may reduce death from any cause and death from bladder cancer over time; however, the results include the possibility
of no effect. We are uncertain whether the risk of serious complications up to 30 days may be increased. We are also uncertain as to
whether the risk of recurrence over time or the risk of minor complications up to 30 days changes. We were unable to conduct any of
the preplanned subgroup analyses, in particular, analyses based on extended lymph node dissection templates, clinical tumor stage, and
use of neoadjuvant chemotherapy that may be important effect modifiers. Important additional data is expected from a larger, ongoing
trial that will also consider the role of neoadjuvant chemotherapy. Inclusion of this trial in the meta-analysis may help address the issue
of imprecision which was a common reason for downgrading the certainty of the evidence.
P L A I N L A N G U A G E S U M M A R Y
Extended versus standard lymph node dissection in patients with bladder cancer undergoing total bladder removal
Review question
When removing the whole bladder for bladder cancer, how does removing the lymph nodes from a large area (extended lymph node
dissection) compare to only from a smaller area (standard lymph node dissection)?
Background
People with advanced cancer of the bladder that has spread into the deep muscle layers (but not outside the bladder) often have an
operation to remove the whole bladder. As part of this operation, surgeons remove lymph nodes in that part of the body, which is
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an important part of the immune system. Traditionally, only the lymph nodes close to the bladder and its major blood vessels were
removed. This is called a standard lymph node dissection which removes lymph nodes as high up as to where the main blood vessels
for the pelvis and the leg split up. Some people think that also removing lymph nodes further away from the bladder is better in getting
rid of cancer. This is called an extended lymph node dissection. It removes lymph nodes as high up as the blood vessels that supply the
lower part of the intestines. We don’t know whether this indeed helps people live longer and not die from bladder cancer and how the
unwanted effects compare.
Study characteristics
We included only studies in which chance determined whether people got a standard or extended lymph node dissection that was
reported in literature up to April 29, 2019.
Key results
We found only one such study that answered our review question. This study was done at 16 large hospitals in Germany and included
401 men and women with bladder cancer.
We found that having an extended node dissection may make people less likely to die for any reason or to die from bladder cancer over
time, although our confidence in this result is limited.
We are uncertain whether an extended node dissection causes more serious unwanted effects than a standard lymph node dissection.
We are also uncertain whether an extended node dissection makes cancer less likely to come back over time and causes a similar risk of
not-so-serious unwanted effects compared to a standard lymph node dissection.
Certainty of the evidence
The certainty of evidence for these findings was low or very low, meaning that the true outcomes may be very different from what this
review found.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Participant or population: Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquart ile range) 59 to 74)
Country: Germany
Setting: Muticenter/ Inpat ient
Intervention: Extended lymph node (LN) dissect ion
Comparison: Standard lymph node (LN) dissect ion
Outcomes of participants
(studies)




Anticipated absolute effects∗ (95% CI)
Risk with standard LN dis-
section
Risk difference with Ex-
tended LN dissection
Time to death from any
cause
(absolute ef fect size est i-











503 per 1,000 83 fewer per 1,000
(174 fewer to 24 more)
High
600 per 1,000 3 89 fewer per 1,000
(193 fewer to 25 more)
Time to death from bladder
cancer
(absolute ef fect size est i-











355 per 1,000 91 fewer per 1,000
(176 fewer to 19 more)
Moderate
491 per 1,000 4 114 fewer per 1,000













































































































































Clavien-Dindo grade ≥ 3
complications
assessed with: Clavien-
Dindo classif icat ion (Grade










286 per 1,000 37 more per 1,000
(46 fewer to 149 more)
High
565 per 1,000 6 73 more per 1,000
(90 fewer to 294 more)
Time to recurrence
(absolute ef fect size est i-
mates based on recurrence










408 per 1,000 52 fewer per 1,000
(146 fewer to 64 more)
Moderate
453 per 1,000 7 55 fewer per 1,000
(158 fewer to 68 more)
High
574 per 1,000 7 62 fewer per 1,000
(184 fewer to 73 more)
Clavien-Dindo grade ≤ 2
complications 8
assessed with: Clavien-
Dindo classif icat ion (Grade










414 per 1,000 25 fewer per 1,000
(108 fewer to 79 more)
Disease-specific quality of
life 9













































































































































*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; HR: Hazard rat io; LN: Lymph node; RR: Risk rat io; RCT : Randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded by one level for study lim itat ions: high risk of performance and detect ion bias
2 Downgraded by one level for imprecision: conf idence interval crossed the line of no dif ference and the assumed threshold
of a clinically important dif f erence (included benef it and no benef it )
3 Baseline risk for death f rom any cause in the standard LN dissect ion group was assumed to be 60% (high risk) at 5 years as
reported in Abd El-Lat if 2012; observat ional study.
4 Baseline risk for death f rom bladder cancer in the standard LN dissect ion group was assumed to be 49.1% (high risk) at 5
years as reported in Simone 2013; observat ional study.
5 Downgraded by two levels for imprecision: conf idence interval crossed the line of no dif ference and the assumed threshold
of a clinically important dif f erence; wide conf idence interval (included both benef it and harm)
6 Baseline risk for Clavien-Dindo grade ≥ 3 complicat ions in the standard LN dissect ion group was assumed to be 56.5%
(high risk) at 30 days as reported in Brossner 2004; observat ional study.
7 Baseline risk for recurrence in the standard LN dissect ion group was assumed to be 45.3% (moderate risk) and 57.3% (high
risk) at 5 years as reported in Abol-Enein 2011 and in Simone 2013, respect ively; both observat ional studies.
8 We could not ascertain this outcome in observat ional studies













































































































































B A C K G R O U N D
Description of the condition
In accordance with 2018 GLOBOCAN data, urothelial carcinoma
of the bladder is the 10th most common malignancy worldwide,
with 549,393 new cases and 200,000 cancer-related deaths (Bray
2018). In the United States, bladder cancer comprises 5% of new
cancer diagnoses and is the sixth most prevalent malignancy (
American Cancer Society).
About 90% of affected patients are older than 55 years (median
age: 73 years); men are three to four times more likely than women
to develop the disease according to the key statistics for bladder
cancer (American Cancer Society; NCCN Guideline 2019). Ap-
proximately 75% of the newly diagnosed patients have non-mus-
cle invasive bladder cancer (tumor that spreads to the mucosa [car-
cinoma in situ, Ta] and lamina propria [stage T1]), while the re-
maining 25% of the patients have muscle-invasive carcinoma (tu-
mor invasion to the muscle layer of the bladder; stage T2) (Burger
2013; Smith 2014). Prognosis depends on the types of bladder
cancer, with five-year rates ranging from 96% for non-muscle inva-
sive bladder cancer to 5% for metastatic cases (NCCN Guideline
2019). An estimated 17,240 deaths were caused by bladder cancer
in the US in 2018 (American Cancer Society).
Risk factors for urothelial bladder cancer vary (Burger 2013;
Chang 2017; EAU Guideline 2018). Smoking and occupational
exposure to chemicals are well-known environmental risk factors.
With regard to medical conditions, radiotherapy for other ma-
lignancies of pelvic organs and chronic urinary tract infections
are strongly related to the development of bladder cancer. Other
controversial risk factors are dietary factors, gender, race, and so-
cioeconomic status (Burger 2013; Chang 2017; EAU Guideline
2018). Genetic instability may also be implicated in the genesis of
bladder cancer (Chang 2017; Figueroa 2014).
Description of the intervention
Lymph node dissection (LND) is a surgical procedure in which the
lymph nodes in the tumor area or in the whole lymphatic drainage
area are also removed in addition to surgical management of pri-
mary cancer. Radical cystectomy (RC) (removal of the bladder)
with bilateral pelvic lymph node dissection (PLND) and cisplatin-
based neoadjuvant or adjuvant chemotherapy is the gold standard
for the management of resectable (able to be removed by surgery)
non-metastatic muscle-invasive bladder cancer and for non-mus-
cle-invasive high grade urothelial carcinoma that is refractory to
intravesical therapy (Chang 2017; EAU Guideline 2018; Herr
2001; NCCN Guideline 2019; Stein 2001; Shabsigh 2009). The
suggested PLND templates for their treatment are as follows:
• Limited PLND: removal of lymph nodes limited to
obturator or peri-vesical fossa, lying laterally by the external iliac
vein and are present medial to the obturator nerve (Brossner
2004; Holmer 2009; Hori 2013)
• Standard PLND: removal of lymph nodes, along with the
obturator and external, internal, and common iliac nodes up to
the crossing of the ureter (Chang 2017; Simone 2013)
• Extended PLND: removal of lymph nodes, along with the
aortic bifurcation and common iliac vessels, the genitofemoral
nerve, the circumflex iliac vein and lymph node of Cloquet, and
the internal iliac vessels (Holmer 2009; Simone 2013).
• Super-extended PLND: LND is performed up to the
inferior mesenteric artery with a template of extended PLND
(Abol-Enein 2011).
In this review, standard PLND refers to limited and standard
PLND as defined above, and extended PLND refers to any tem-
plate beyond the standard PLND.
Adverse events associated with the intervention
There are several complications inherent to PLND, including
ureteral injury, major vascular injury, obturator nerve injury, pelvic
lymphocele (a collection of lymphatic fluid not bordered by ep-
ithelial lining), deep venous thrombosis, and leg/scrotal edema
(Kavoussi 1993). A large retrospective study reported 28% early
complications and 2.6%-3% perioperative mortality rates for
PLND (Stein 2001). However, when comparing complication
rates according to the extent of PLND (i.e. extended versus stan-
dard or limited PLND) and age (octogenarians versus non-oc-
togenarians), no detectable differences were reported except for
prolonged operation time in extended PLND performed laparo-
scopically (Brossner 2004; Finelli 2004; Grabbert 2017; Holmer
2009; Poulsen 1998). Moreover, a prospective multicenter study
reported no significant adverse events to be associated with ex-
tended PNLD (Leissner 2004).
How the intervention might work
The incidence of lymph node metastasis at RC for bladder cancer
ranges from 13% to 26% and is associated with a high risk of tumor
recurrence and progression (Leissner 2004; Poulsen 1998; Stein
2001). PLND potentially has therapeutic importance by removing
undetected metastatic lymph nodes, and thus, for providing a
chance of cure for some patients for whom radical cystectomy
alone would have been insufficient. Furthermore, lymph node
dissection is important for accurate pathological staging and helps
stratify the risk, therefore, helping determine the need for adjuvant
systemic chemotherapy after RC (Ku 2010; Youssef 2011).
Extended PLND also captures lymph node metastases beyond the
common iliac bifurcation yielding an ever larger number of nodes
(Vazina 2004). Removing more lymph nodes is hypothesized to
reduce the incidence of recurrence and potentially provide better
recurrence-free, cancer-specific, and overall survival (Herr 2002;
Konety 2003; Leissner 2000; Steven 2007).
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Why it is important to do this review
Until recently, the evidence for the benefits and harms of extended
PLND over those of standard PLND originated only from non-
randomized trials (Abd El-Latif 2012; Abol-Enein 2011; Brossner
2004; Ku 2010; Simone 2013; Wang 2013) which had many in-
herent limitations. Systematic reviews and meta-analyses based on
these studies have been plagued by the same limitations (Bi 2014;
Bruins 2014; Palmer 2011; Tilki 2013).
This Cochrane review was triggered by the publication of the first
randomized controlled trial on this topic. In contrast to prior sys-
tematic reviews, this review stands out for its rigorous methodol-
ogy which includes a registered protocol, a comprehensive search,
a focus on patient-important outcomes and the application of
GRADE. We expect this review to be helpful to clinicians, guide-
line developers, and policy-makers in helping them establish an
evidence-based role for extended PLND when treating muscle-
invasive bladder cancer.
O B J E C T I V E S
To assess the effects of extended versus standard PLND in patients
undergoing cystectomy to treat muscle-invasive (cT2 and cT3) and
treatment refractory, non-muscle-invasive (cT1 with or without
carcinoma in situ) urothelial carcinoma of the bladder.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review is based on a previously published protocol (
CRD42018116290). For details on the differences between the
previous protocol and the method followed here, please refer to the
’Differences between protocol and review’ section. We included
randomized controlled trials (RCTs) as they offer more reliable re-
sults. We excluded quasi-randomized and nonrandomized studies,
cohort studies, case series, cross-over trials, and cluster-random-
ized trials. We did not exclude studies on the basis of publication
status or language.
Types of participants
We included studies of participants with urothelial carcinoma of
the bladder undergoing RC with PLND with curative intent. Par-
ticipants of these trials underwent histological confirmation of
urothelial carcinoma based on transurethral resection of the blad-
der (TURBT) and cross-sectional imaging (usually computer to-
mography (CT) and/or magnetic resonance imaging (MRI) indi-
cating clinically localized disease with or without suspected locore-
gional lymphatic spread (N0 or N1) but without distant metas-
tases (M0). Eligible clinical tumor stages were T2 and T3, as well
as treatment-refractory T1 and carcinoma in situ. We excluded
trials of participants with locally advanced, but unresectable, blad-
der urothelial carcinoma with pelvic fixation (clinical stage T4)
Types of interventions
We planned to investigate the following experimental and com-
parator interventions.
Experimental interventions
We planned to include studies that had used templates for ex-




⋄ cranial: inferior mesenteric artery, caudal: pelvic
floor (circumflex iliac vein), both lateral: genitofemoral nerve,
both medial: ureter, dorsal: rectum, or




⋄ cranial: common iliac bifurcation (bifurcation of
the internal and external iliac artery), caudal: pelvic floor
(circumflex iliac vein), both lateral: genitofemoral nerve, both
medial: ureter, dorsal: obturator nerve
Concomitant interventions had to be the same in the experimental
and comparator groups to ensure fair comparisons.
Types of outcome measures
We did not exclude trials if they met inclusion criteria but did not
report one or several of our primary or secondary outcomes.
Primary outcomes
• Time to death from any cause (overall survival, time-to-
event outcome)
• Time to death from bladder cancer (disease-specific
survival, time-to-event outcome)
• Clavien-Dindo III-V complications (dichotomous
outcome)
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Secondary outcomes
• Time to recurrence (recurrence-free survival, time-to-event
outcome)
• Clavien-Dindo I-II complications (dichotomous outcome)
• Disease-specific quality of life (continuous outcome)
Method and timing for outcome measures
• Time to death from any cause: as measured from the time
of randomization to the time of death due to any cause
• Time to death from bladder cancer: as measured from the
time of randomization to the time of death due to bladder cancer
• Time to recurrence: as measured from the time of
randomization to the time of the first confirmed recurrence
◦ Definition of recurrence: judged based on the
imaging, such as computed tomography, with or without biopsy
• Clavien-Dindo I-V complications: we used the Clavien-
Dindo classification system to assess surgical complications
(Dindo 2004). If an eligible study’s authors had not used the
Clavien-Dindo system, we judged the adverse events by severity
using the information available in the studies
• Disease-specific quality of life: measured by validated
instruments (e.g. the 12-item Short Form (SF-12), 36-item
Short Form (SF-36), Functional Assessment of Cancer Therapy
(FACT) questionnaire, or EORTC Quality of Life
Questionnaire version 3.0
We considered complications that appeared within six months af-
ter the randomization. If we were unable to retrieve the informa-
tion required to assess time-to-event outcomes, we tried to assess
the number of events per the total number of participants included
in each relevant study for dichotomized outcomes at 12, 24, 36,
and 60 months for death from any cause, death from bladder can-
cer, and recurrence.
Search methods for identification of studies
We performed a comprehensive literature search with no restric-
tions on language or the status of publication. We planned to re-
run searches within three months prior to the anticipated publi-
cation of the review, should the original search date have fallen
outside of this timeframe.
Electronic searches
We searched the following sources for relevant literature that was
published since the inception of each database (Appendix 1). The
date of the last search for all databases was April 29, 2019.
• PubMed (late 1940s - present);
• Embase (Elsevier, 1947 - present);
• Cochrane Controlled Trials (Issue 4, April 2019);
• Web of Science (1900 - 2019);
• LILACS (Latin American and the Caribbean Health
Sciences Literature; http://lilacs.bvsalud.org/en/).
We also searched the following:
• ClinicalTrials.gov (https://www.clinicaltrials.gov/);
• World Health Organization ( WHO) International Clinical
Trials Registry Platform search portal ( http://apps.who.int/
trialsearch/).
If we detected any additional relevant keywords during our litera-
ture search, we modified our electronic search strategies to incor-
porate these terms and documented the changes.
Searching other resources
We tried to identify other potentially eligible trials or ancillary
publications by searching the reference lists of included trials, re-
views, and meta-analyses. We also contacted the authors of tri-
als included in this review to identify any further studies that we
may have missed. We also searched the meeting proceedings of the
American Urological Association, European Association of Urol-
ogy, and American Society of Clinical Oncology annual meetings
for the last three years (2016 to 2018) for relevant abstracts of
unpublished studies.
Data collection and analysis
In this review, we followed the methodological recommendations
provided by the Cochrane Handbook (Higgins 2017a).
Selection of studies
Two review authors (ECH and NS) independently assessed ab-
stracts and titles to determine which studies should be assessed
further using the Covidence software. They investigated all po-
tentially relevant records, such as full texts and mapped records
to studies, and classified them as studies that should be included,
excluded, await classification, or as ongoing studies in accordance
with the criteria provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2017a). We resolved any discrep-
ancies through consensus or by recourse to a third review author
(PD). If a resolution was not possible, we designated the study as
’awaiting classification’. We documented the reasons for the exclu-
sion of studies in the ’Characteristics of excluded studies’ table. We
presented an adapted PRISMA flow diagram showing the process
of study selection (Liberati 2009) (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
In this review, two authors (ECH and NS) independently extracted
relevant data using a data extraction form. We based this form
on the recommendations of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2017a) and pilot-tested it before
using it in our analysis. These authors resolved any potential dis-
agreements by consensus or through discussion with a third au-
thor (PD). In addition, when necessary, we contacted the original
authors of a given study. We collected and used the most detailed
numerical data that might facilitate similar analyses of included
studies. We have presented all characteristics of the included stud-
ies in the ‘Characteristics of included studies’ table.
• Record citation (e.g. authors’ names and article title).
• Details of methods: study design and date when the study
was conducted.
• Details of participants: setting; country; the number of
included participants; age; sex; inclusion and exclusion criteria;
tumor stage (clinical or pathologic T category); pathologic nodal
stage; positive surgical margin; neo- or adjuvant chemotherapy.
• Details of interventions: the number of participants
randomly assigned to each intervention group and PLND
boundaries in each group.
• Details of outcomes: outcomes included in this review that
were assessed in each study, including how each was measured
and the times at which they were measured.
• Funding sources for the study.
• Declarations of interest among the primary study authors.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents, or
multiple reports for a primary study, we maximized the yield of
information by mapping all publications to unique studies and
collating all available data. We used the most complete data set
aggregated across all known publications. In case of doubt, we
prioritized the publication that had reported the longest follow-
up associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two authors (ECH and NS) independently assessed the risks of
bias for each included study. We resolved the disagreements by
consensus or by consulting with a third author (PD). We used the
Cochrane “Risk of bias” assessment tool for the following domains
(Higgins 2017b).
• Random sequence generation (selection bias);
• Allocation concealment (selection bias);
• Blinding of participants and personnel (performance bias);
• Blinding of outcome assessments (detection bias);
• Incomplete outcome data (attrition bias);
• Selective reporting (reporting bias);
• Other potential sources of bias (e.g. baseline imbalance).
We judged the risk of bias by categorizing them into domains,
such as “low risk,” “high risk,” or “unclear risk.” We presented
the results of this assessment graphically. For selection bias and
reporting bias, we evaluated the risks of bias at the trial level.
For performance bias (blinding of participants and personnel), we
defined all outcomes as similarly susceptible to performance bias
and assessed them in one group.
For detection bias (blinding of outcome assessments), we grouped
outcomes as susceptible to detection bias (subjective) or not sus-
ceptible to detection bias (objective) outcomes. We defined the
following outcome measures as subjective:
• time to death from bladder cancer;
• time to recurrence;
• Clavien-Dindo I-II complications;
• disease-specific quality of life.
We defined the following outcomes as objective:
• time to death from any cause;
• Clavien-Dindo III-V complications.
We assessed attrition bias (incomplete outcome data) from an out-
come-specific perspective. We summarized the risk of attrition bias
across domains for each outcome in each included study, as well as
across the studies and domains for each outcome. This was done in
accordance with the approach for summary assessment of the risk
of bias presented in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2017b).
Measures of treatment effect
We expressed dichotomous data as RRs with a 95% confidence in-
terval (CI). For continuous outcomes measured on the same scale,
we estimated the intervention effect using the mean difference
(MD) with a 95% CI. For continuous outcomes that measured
the same underlying concept (e.g. disease-specific quality of life),
but on different measurement scales, we calculated the standard-
ized mean difference (SMD). We expressed time-to-event data as
HRs with 95% CI or used an indirect estimation method if HRs
were not given (Parmar 1998; Tierney 2007).
Unit of analysis issues
The units of analysis were each individual participant. If we had
identified trials with more than two intervention groups for inclu-
sion in this review, we handled these in accordance with the guid-
ance provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
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Dealing with missing data
We planned to obtain missing data from the original authors of
each study included here, if feasible; we further planned to perform
intention-to-treat analyses if data were available. Otherwise, we
performed available-case analyses. We investigated attrition rates
(e.g. dropouts, losses to follow-up, and withdrawals) and critically
appraised any issues of missing data. We did not plan to impute
missing data.
Assessment of heterogeneity
We planned to assess heterogeneity. However, we included only
one RCT and, therefore, the assessment of heterogeneity was not
possible.
Assessment of reporting biases
We tried to obtain study protocols to assess selective outcome
reporting. As we included only one study, we could not use funnel
plots to assess small study effects.
Data synthesis
As we included only one RCT, we only re-analyzed and re-
ported single study data using Review Manager 5 software (Review
Manager 2014) in accordance with the guidelines contained in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2017a).
Subgroup analysis and investigation of heterogeneity
We expected the following characteristics to introduce clinical het-
erogeneity and planned to carry out subgroup analyses to investi-
gate interactions.
• Extended PLND template (if different PLND templates
were used in various studies);
• Clinical tumor stage (non-muscle invasive [e.g., T1G3]
versus muscle-invasive disease [e.g. ≥ T2]);
• Neoadjuvant chemotherapy (neoadjuvant versus no
neoadjuvant chemotherapy).
We restricted subgroup analyses to the primary outcomes only.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect size, if applicable:
• Restricting the analysis by taking the risk of bias into
account and excluding studies classified as having a high or
unclear risk of bias.
However, we could not perform any subgroup or sensitivity anal-
yses due to the lack of relevant data.
’Summary of findings’ table
Main outcomes for the ’Summary of findings’ table
We present a ’Summary of findings for the main comparison’ that
reports on the following measures of outcome listed according to
priority. One review author (PD) determined the priorities of the
measures of outcome using content expertise:
• Time to death from any cause;
• Time to death from bladder cancer;
• Clavien-Dindo III-V complications;
• Time to recurrence;
• Clavien-Dindo I-II complications;
• Disease-specific quality of life.
We presented the findings and the certainty of the available ev-
idence according to the GRADE methodology (Schünemann
2017).
We assessed the overall certainty of evidence for each outcome ac-
cording to the GRADE approach, which considers five criteria that
are related not only to internal validity (risk of bias, inconsistency,
imprecision, and publication bias) but also to external validity (the
directness of results) (Guyatt 2008). Two authors ( ECH, NS)
of this review independently rated the certainty of evidence for
each outcome as “high”, “moderate”, “low”, or “very low”. We re-
solved discrepancies by consensus or, if needed, by the arbitration
of a third author ( PD). We presented a summary of the evidence
for the main outcomes in the ’Summary of findings’ table, which
we generated using the Gradepro GDT ( https://gradepro.org/).
This table provides key information about the best estimate of the
magnitude of an effect in relative terms and presents absolute dif-
ferences for each relevant comparison of alternative management
strategies, numbers of participants and studies addressing each im-
portant outcome, as well as the rating of our overall confidence in
the effect estimates for each outcome (Guyatt 2011; Schünemann
2017).
R E S U L T S
Description of studies
Results of the search
Our literature search yielded 774 references to which we added
an additional 15 records that were identified by searching trial
registries and manual searches. After the exclusion of duplicates, we
screened 677 references at the title and abstract stage. Of these 677
references, five references that were mapped to two unique studies
entered the full-text screening stage. We ultimately included one
study in the qualitative analyses (Figure 1).
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Included studies
Source of data
We identified one RCT (Gschwend 2018). For details, please re-
fer to the ’Characteristics of included studies’ table, Table 1, and
Table 2. The included trial compared extended PLND with stan-
dard PLND during RC for the treatment of bladder urothelial
carcinoma. We contacted the corresponding author of this study
to get additional information and received a response (Appendix
2).
Participants
A total of 458 participants were screened for enrolment. Between
October 2006 and December 2010, 401 participants were ran-
domly assigned to this trial (extended PLND, n = 198; standard
PLND, n = 203). All randomized participants were included in
the analysis.
Interventions and comparators
The study used extended PLND as an intervention and standard
PLND as a comparator. The median follow-up duration was 43
months.
Outcomes
We found reporting of all primary outcomes in the included study
for this comparison. In addition, all secondary outcomes were
reported for the study included, except for disease-specific quality
of life.
Funding sources and conflicts of interest
A pharmaceutical company supported the study, but all authors
declared no conflicts of interest.
Excluded studies
There were no studies excluded at the full-text screening stage.
Studies awaiting classification and ongoing trials
There were no studies awaiting classification. We found one on-
going study, Southwest Oncology Group study S1011, which did
not provide usable outcome data at the time that this review was
written (NCT01224665; ‘Characteristics of ongoing studies’ ta-
ble). Expected date of completion is August 2022.
Risk of bias in included studies
For details, please refer to ’Characteristics of included studies’ sec-
tion, the ’Risk of bias’ table, and the ’Summary of findings for
the main comparison’ for information on the main comparison,
as well as Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation and allocation concealment were
performed adequately; we rated the risk of bias as low.
Blinding
Performance bias
Participants and personnel (surgeons) were not blinded. We rated
the risk of bias as high.
Detection bias
Susceptible (subjective) outcomes (time to death from bladder
cancer, time to recurrence, Clavien-Dindo I-II complications): the
assessors of these outcomes were reported to be unblinded. We
rated the risk of bias for these outcomes to be high.
Not susceptible (objective) outcomes (time to death from any
cause, Clavien-Dindo III-V complications): blinding of outcome
assessors did not appear relevant to these outcomes, therefore, we
rated the risk of bias for them as low.
Incomplete outcome data
Among 203 participants assigned to standard PLND, 13 partici-
pants did not receive standard PLND. Also, in the extended PLND
group (n = 198), 25 participants did not receive extended PLND.
However, all randomized participants (n = 401) were included in
the analysis as intended. We judged the risk of bias as low risk for
all outcomes.
We did not rate the domain of disease-specific quality of life be-
cause this outcome was not investigated in the trial. We reported
the risk of bias as unclear in the table and figures only because this
was the default value.
Selective reporting
Since the study had a planned protocol, and all reported out-
comes and associated analyses corresponded to how these had been
planned, we assigned a judgement of low risk of reporting bias.
Other potential sources of bias
No other potential sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison Impact of
extended versus standard lymph node dissection on overall survival
among patients with urothelial cancer of the bladder
Please refer to the Analysis 1.1 to Analysis 1.7 and Summary of
findings for the main comparison. We also analysed the 90-day
results for complications in the Analysis 1.4 and Analysis 1.7; we
did not describe this below.
Primary outcomes
Time to death from any cause
Extended PLND may reduce the risk of death from any cause
over time as compared to standard PLND (HR: 0.78, 95% CI:
0.57 to 1.07, participants = 401; studies = 1, Analysis 1.1, low-
certainty evidence). Based on the control event risk in this trial
at 5-year follow-up, this corresponds to 83 fewer deaths from any
cause (95% CI: 174 fewer to 24 more) per 1000 participants: 420
deaths for extended PLND compared to 503 deaths per 1000 for
standard PLND.
Based on high-risk control groups as drawn from an observa-
tional study (Abd El-Latif 2012), also at 5-year follow-up, ex-
tended PLND may result in 89 fewer overall deaths (95% CI: 193
fewer to 25 more) per 1000 participants: 511 deaths for extended
PLND compared to 600 deaths per 1000 participants for standard
PLND.
We rated the certainty of evidence as low due to study limitations
(performance bias) and imprecision, given that the CI was con-
sistent both with an appreciable reduction in the risk of overall
deaths as well as a small or no increase in the risk of overall deaths.
Time to death from bladder cancer
Extended PLND may reduce the risk of death from bladder cancer
over time as compared to standard PLND (HR: 0.70, 95% CI:
0.45 to 1.07, participants = 401; studies = 1, Analysis 1.2, low-
certainty evidence). Based on the control event risk of the included
trial at 5-year follow-up, this corresponds to 91 fewer deaths from
bladder cancer (95% CI: 176 fewer to 19 more) per 1000 partic-
ipants: 264 deaths for extended PLND compared to 355 deaths
per 1000 participants for standard PLND.
Based on moderate-risk control groups as drawn from an obser-
vational study (Simone 2013), also at 5-year follow-up, extended
PLND may result in 114 fewer bladder cancer deaths (95% CI:
229 fewer to 24 more) per 1000 participants: 377 deaths for ex-
tended PLND compared to 491 deaths per 1000 participants for
standard PLND.
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We rated the certainty of evidence as low due to study limitations
(performance and detection bias) and imprecision, given that the
CI was consistent both with an appreciable reduction in the risk
of bladder cancer deaths as well as a small or no increase in the
risk of bladder cancer deaths.
Clavien-Dindo grade ≥ 3 complications
We are uncertain whether extended PLND results in more
Clavien-Dindo grade ≥ 3 complications as compared to standard
PLND (RR: 1.13, 95% CI: 0.84 to 1.52, participants = 401; stud-
ies = 1, Analysis 1.3, very low-certainty evidence). Based on the
control event risk in the trial and 30-day follow-up, this corre-
sponds to 37 more complications (95% CI: 46 fewer to 149 more)
per 1000 participants: 323 complications for extended PLND
compared to 286 complications per 1000 participants for standard
PLND.
Based on the high-risk control groups as coming from an observa-
tional study (Brossner 2004) also at 30-day follow-up, extended
PLND may result in 73 more complications (95% CI: 90 fewer to
294 more) per 1000 participants: 638 complications for extended
PLND compared to 565 complications per 1000 participants for
standard PLND.
We downgraded the certainty of evidence by one level due to study
limitations, namely performance bias, and by two levels due to
imprecision, given that the CI was consistent both with a small
reduction in complications, as well as an appreciable increase in
the Clavien-Dindo grade ≥ 3 complications.
Secondary outcomes
Time to recurrence
We are uncertain whether extended PLND reduces the risk of
recurrence over time as compared to standard PLND (HR: 0.84,
95% CI: 0.58 to 1.22, participants = 401; studies = 1, Analysis
1.5, very low-certainty evidence). Based on the control event risk
in the trial included in this analysis and 5-year follow-up, this
corresponds to 52 fewer recurrences (95% CI: 146 fewer to 64
more) per 1000 participants: 356 recurrences for extended PLND
compared to 408 recurrences per 1000 participants for standard
PLND.
Based on the moderate- and high-risk control groups, as drawn
from separate observational studies (Abol-Enein 2011; Simone
2013) at 5-year follow-up, extended PLND may result in 55 fewer
recurrences (95% CI: 158 fewer to 68 more) per 1000 participants:
398 recurrences for extended PLND compared to 453 recurrences
per 1000 participants for standard PLND or 62 fewer recurrences
(95% CI: 184 fewer to 73 more) per 1000 participants: 512 re-
currences for extended PLND compared to 574 recurrences per
1000 participants for standard PLND, respectively. We rated the
certainty of evidence to be very low due to study limitations (due
to performance and detection bias) as well as imprecision, given
that the CI was consistent both with an appreciable reduction in
the risk of recurrence, as well as a small increase in the risk of
recurrences.
Clavien-Dindo grade ≤ 2 complications
The evidence is uncertain whether extended PLND results in sim-
ilar Clavien-Dindo grade ≤ 2 complications compared to stan-
dard PLND.(RR: 0.94, 95% CI: 0.74 to 1.19, participants = 401;
studies = 1, Analysis 1.6, very low-certainty evidence). Based on
the control event risk in the trial included in this analysis and a 30-
day follow-up, this corresponds to 25 fewer complications (95%
CI: 108 fewer to 79 more) per 1000 participants: 389 compli-
cations for extended PLND compared to 414 complications per
1000 participants for standard PLND. We downgraded the cer-
tainty of evidence by one level due to study limitations, namely
performance bias and detection bias, and by two levels due to im-
precision, given that the CI was consistent both with an apprecia-
ble reduction in complications, as well as a small increase in the
Clavien-Dindo grade ≤ 2 complications.
Disease-specific quality of life
We found no studies that reported this outcome.
Subgroup analysis
We were unable to obtain sufficient information to perform the
planned subgroup analyses.
D I S C U S S I O N
Summary of main results
We included only one RCT with 401 participants. The findings of
this systematic review indicate that extended PLND may reduce
overall mortality and bladder cancer mortality over time but both
results include the possibility of no effect. The evidence is uncer-
tain about the effect of extended PLND on time to recurrence.
With regard to complications, we are uncertain whether extended
PLND increases Clavien-Dindo grade ≥ 3 complications and re-
sults in similar Clavien-Dindo grade ≤ 2 complications for up to
30 days.
We were unable to find evidence for the effect of extended PLND
on disease-specific quality of life and were unable to conduct any
of our preplanned secondary analyses based on lymph node dis-
section templates, tumor stage or receipt of neoadjuvant chemo-
therapy.
16Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Overall completeness and applicability of
evidence
Findings of this review were based on only one RCT that was
performed by experienced high-volume surgeons at tertiary med-
ical centers which may limit the generalizability of its findings.
Quality control of the treatment arms could have been improved
by measures such as intraoperative photographs taken to ensure
the completeness of extended PLND and to document that dis-
section in the standard PLND arm did not extend beyond the
intended boundaries. Moreover, the study did not investigate the
effect of extended PLND in a neoadjuvant or adjuvant setting
which are recommended by current guidelines (Chang 2017; EAU
Guideline 2018; NCCN Guideline 2019) and may represent ef-
fect modifiers.
Quality of the evidence
Overall, we judged the potential risk of bias of the included trial
as unclear. While the study used appropriate methods of random-
ization and allocation concealment, thereby raising no concerns
about selection bias, it used an open-label design (no blinding of
participants and personnel) raising concerns about performance
bias. Also, outcome assessors were not blinded raising concerns
about detection bias. The latter does not apply to outcomes that
could be objectively measured such as time to death from any cause
and Clavien-Dindo III-V complications for which we judged the
risk of detection bias as low. Since all randomized participants were
included in the analyses for all investigated outcomes, we judged
the risk of attrition bias as low.
We judged the certainty of the evidence body as low or very low
for most outcomes due to these study limitations as well as wide
confidence intervals and resulting clinically important impreci-
sion of the results. For the Clavien-Dindo complications and time
to recurrence outcomes, we judged the certainty of the evidence
body as very low, due to the aforementioned reasons. In addition,
very wide confidence intervals led to downgrading (two levels) for
imprecision.
Potential biases in the review process
• It is possible (although unlikely) that additional studies may
have been conducted but not yet published, or that we failed to
identify additional studies that do exist despite our
comprehensive search.
• The study included some clinical stage T1 disease
participants. Given that the aggressiveness of cancer is somewhat
different from that of muscle-invasive disease (clinical stage ≥
T2 disease), this could be a source of bias, possibly resulting in
an underestimate of the effect size.
Agreements and disagreements with other
studies or reviews
We identified four systematic reviews with nonrandomized con-
trolled trials on this topic (Bi 2014; Bruins 2014; Palmer 2011;
Tilki 2013).
Bi 2014 performed a systematic review that included six studies
comparing extended PLND and nonextended PLND. The defi-
nition of LND template in their review was similar to that used
in our review. In line with our results, the pooled data indicated
that extended PLND provided a better recurrence-free survival as
compared to nonextended PLND. Subgroup analysis showed that
participants with ≥ pathologic T3 disease and regardless of lymph
node involvement, also had a recurrence-free survival benefit from
extended PLND. The level of evidence (LOE) of the included
studies was rated according to the criteria developed by the Centre
for Evidence-Based Medicine in Oxford, UK, (OCEBM Levels of
Evidence Working Group) but the risk of bias was not assessed.
Bruins 2014 performed a systematic review that included 23 stud-
ies to evaluate the impact of the extent of LND on oncologic out-
comes. They could not perform a meta-analysis due to study het-
erogeneity; instead, they assessed the risk of bias using the risk of
bias tool developed by Cochrane (Reeves 2011). They concluded
that despite the poor quality of the data, extended PLND might
improve oncologic outcomes as compared to lesser degrees of dis-
section, although extending the dissection up to inferior mesen-
teric artery was unlikely to yield any further benefits. Moreover,
extended PLND seemed to not increase perioperative morbidity.
These results are somewhat different from our results.
Palmer 2011 performed a systematic review, including three stud-
ies that compared extended and limited PLND. The pooled rel-
ative risk for recurrence-free survival was 1.23 (95% CI 1.07 to
1.42; P = 0.004) in favour of extended PLND. However, they did
not provide information on the overall or disease-specific survival
or detailed findings regarding the complications. They rated the
certainty of evidence using GRADE and assessed the risk of bias
using the risk of bias tool developed by Cochrane (Reeves 2011).
Tilki 2013 summarized the existing data on the value of lym-
phadenectomy for staging and disease-free survival. They con-
cluded that extended PLND may influence disease-free survival.
However, they included several studies that evaluated the use of
lymph node retrieval count as a surrogate for the extent of LND.
It seems inaccurate to use the LN count to represent the extent of
the LND template, instead of using an anatomic landmark (Dorin
2011; Meijer 2012).
This systematic review is the first to focus on the RCT results for
both oncologic outcomes and intervention-related complications
and providing absolute effect size estimates. We believe that our
systematic review provides the most reliable summary of evidence
on this topic to date.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This is the first systematic review based on the only available RCT
in this field. Based on the findings of this review, extended PLND
may improve overall survival and cancer-specific survival, although
our results include the possibility of no effect. We are uncertain
whether extended PLND results in more Clavien-Dindo grade ≥ 3
complications for up to 30 days. We are also uncertain whether re-
currence-free survival is improved by extended PLND and whether
Clavien-Dindo grade ≤ 2 complications rates are similar to stan-
dard PLND up to 30 days. We found no evidence from the RCT
for other patient-important outcomes, such as quality of life. As
a result, there is insufficient information to balance the possible
advantages of extended PLND against the potential adverse effects
on patients.
Implications for research
Given that the certainty of evidence for the patient-important
outcomes considered in this review was only low or very low, future
studies are required. Important additional data is expected from
a larger, ongoing trial (NCT01224665) that will also consider
the role of neoadjuvant chemotherapy. We expect to update this
review once the result becomes available; inclusion of this trial in
the meta-analysis may help address the issue of imprecision which
was a common reason for downgrading. Based on its protocol, we
do not expect it to provide information on quality of life as an
important secondary outcome. In the absence of additional trials,
important information on treatment-related harms, in particular,
surgical complications rates of extended PLND, when performed
in the community setting outside of tertiary care centers, could
come from well designed, ideally prospective observational studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gschwend 2018
Methods Study design: Prospective randomized phase-III trial (1:1) study
Statistical design: N/A
Setting/Country: Multicenter/Germany
Dates when study was conducted: February 2006 to August 2010
Participants Ethnicity: likely German
Inclusion criteria
• Histologically proven, locally completely resectable (T1G3 - T4a, Nx), invasive
urothelial bladder cancer
• Age ≥ 18 years
• Written consent of the patient
• Patient compliance and geographic proximity to allow adequate follow-up
Exclusion criteria
• Histologically or by imaging diagnostics-proven organ metastases
• Radiographic evidence of enlarged lymph nodes (> 1 cm) above the aortic
bifurcation in conjunction with pelvic lymph node metastases
• Radiographic or other evidence of T4b-tumor (infiltration of the pelvic wall or
other organ systems)
• Prior neoadjuvant chemotherapy of bladder cancer
• Prior previous pelvic lymphadenectomy
• Prior radiotherapy to the pelvis
• Internal medical or anesthetic risk factors that require a short operation time
• Palliative cystectomy (e.g. bulky-disease, infiltration of adjacent structures)
• Evidence of another tumor restricting life expectancy of the patient
Total number of participants randomly assigned
• Screened: 458
• Eligible: 401
Group A (Extended lymph node dissection)
• Number of all participants randomly assigned: 198
• Age: median 67 (IQR: 59-74)
• Gender (male/female): 151/47
• Tumor clinical stage: N/A
• Tumor pathologic T stage (T1/T2/T3/T4, %): 31 (16)/88 (44)/63 (32)/16 (8.1)
• Removed LN number: median 31 (IQR 22-47)
• Pathologic N stage (Nx/N0/N+, %): 2 (1.0)/152 (77)/44 (22)
• Positive surgical margin (R0/Rx/R+, %): 179 (90)/2 (1.0)/17 (8.6)
• Neoadjuvant chemotherapy: N/A
• Adjuvant chemotherapy (%): 28 (14)
Group B (Standard lymph node dissection)
• Number of all participants randomly assigned: 203
• Age: median 68 (IQR:61-73)
• Gender (male/female): 163/40
• Tumor clinical stage: N/A
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Gschwend 2018 (Continued)
• Tumor pathologic T stage (T1/T2/T3/T4, %): 24 (12)/81(40)/68(34)/30 (15)
• Removed LN number: median 19 (IQR 12-26)
• Pathologic N stage (Nx/N0/N+, %): 0 (0)/147 (72)/56 (28)
• Positive surgical margin (R0/Rx/R+, %): 181 (89)/4 (2.0)/18 (8.9)
• Neoadjuvant chemotherapy: N/A
• Adjuvant chemotherapy (%): 30 (15)
Interventions Group A (Extended lymph node dissection): Removal of at least 10 out of 14 LND
fields and resection of 12 or more LNs were mandatory
• Lymph node dissection template
◦ Proximal: inferior mesenteric artery
◦ Distal: pelvic floor
◦ Both lateral: genitofemoral nerve
◦ Dorsal: pelvis and rectum
Group B (Standard lymph node dissection): Removal of at least four out of six LND
fields as well as resection of four or more LNs was demanded
• Lymph node dissection template
◦ Proximal: bifurcation of internal and external iliac artery
◦ Distal: pelvic floor
◦ Both lateral: the genitofemoral nerve
◦ Dorsal: obturator nerve
Follow-up: median 43 months
Outcomes Primary outcomes
• Recurrence-free survival (RFS)
• How measured: computed tomography (CT), or death
• Time points measured: every 3 months in the first year and then every 6 months
up to five years postoperatively
• Time point reported: postoperative 5 years
Secondary outcomes
• Cancer-specific survival (CSS), overall survival (OS), localization of tumor
recurrence, influence of adjuvant chemotherapy, influence on histopathologic N stage
• How measured: CSS: death from bladder cancer, OS: death from any cause,
localization of tumor recurrence: CT scan, influence of adjuvant chemotherapy:
survival analysis, influence on histopathologic N stage: survival analysis
• Time points measured: every 3 months in the first year and then every 6 months
up to five years postoperatively
• Time points reported: postoperative 5 years
Safety outcomes
• Complication rate
• How measured: Clavien-Dindo grades (≥ 3 and ≤ 2)
• Time points measured: postoperative 30 days and 90 days
• Time points reported: postoperative 5 years
Funding Sources The study was funded by Lilly Deutschland GmbH, The funder had no role in study
design, data collection, data analysis, data interpretation, or writing of the report. The
sponsor of the trial was the AUO of the German Cancer Society. Trial design, conduct,
and analysis were done by the AUO, independent of all funding bodies
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Gschwend 2018 (Continued)
Declarations of interest None
Notes Protocol: NCT01215071
Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: The randomiza-
tion list was created upfront by a statistician
and organized with blocks per 8 patients.
The blocks were assigned to trial sites con-
secutively. For randomization, the patient
was assigned to the next free consecutive
randomization number of the site’s open
block
Comment: This method of random se-
quence generation was considered to have
low risk of bias
Allocation concealment (selection bias) Low risk Quote from publication: ”a randomiza-
tion fax was sent from the individual par-
ticipating site to the AUO head-office (H.
Rexer) who managed the concealed ran-
domisation list“
Comment: Central registration. This
method may ensure allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from publication: ”Open-label
trial (reported in the study protocol)“
Comment: Participants and personnel
were not blinded; therefore risk of perfor-
mance bias was considered to be high
Blinding of outcome assessment (detection
bias)
Subjective outcomes (susceptible to detec-
tion bias); time to death from bladder can-
cer, time to recurrence, Clavien-Dindo I-II
complications
High risk Quote from publication: ”The outcome
was assessed by the local investigator
(CRFs, Questionaires, CT scans etc.).
There was no blinding (reply from study
investigator)
Comment: Outcome assessor was not
blinded; therefore risk of detection bias was
considered to be high
Blinding of outcome assessment (detection
bias)
Objective outcomes (not susceptible to de-
tection bias); time to death from any cause,
Clavien-Dindo III-V complications
Low risk Comment: Objective outcomes are not
likely affected by lack of blinding
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Gschwend 2018 (Continued)
Incomplete outcome data (attrition bias)
Time to death from any cause
Low risk Comment: Intention-to-treat analysis was
performed. All participants included in the
analysis
Incomplete outcome data (attrition bias)
Time to death from bladder cancer
Low risk Comment: Intention-to-treat analysis was
performed. All participants included in the
analysis
Incomplete outcome data (attrition bias)
Clavien-Dindo III-V complications
Low risk Comment: Intention-to-treat analysis was
performed. All participants included in the
analysis
Incomplete outcome data (attrition bias)
Time to recurrence
Low risk Comment: Intention-to-treat analysis was
performed. All participants included in the
analysis
Incomplete outcome data (attrition bias)
Clavien-Dindo I-II complications
Low risk Comment: Intention-to-treat analysis was
performed. All participants included in the
analysis
Incomplete outcome data (attrition bias)
Disease-specific quality of life
Unclear risk Comment: The included study did not in-
vestigate this outcome.
Selective reporting (reporting bias) Low risk Comment: Protocol was provided and all
predefined outcomes were reported
Other bias Low risk Comment: Not detected
AUO :AssociationofUrologicOncology
CRF: case report forms





N ( Nx/N0/N+): extent of cancer within nearby lymph nodes (Nx: the lymph nodes could not be assessed, N0: no cancer found in
the lymph nodes, N+ cancer found in the lymph nodes)
N/A:notavailable
OS: overall survival
R (R0/Rx/R+): residual tumor (R0: no cells at surgical margin, Rx: residual tumor cannot be assessed, R+: residual tumor present at
surgical margin)
RFS: recurrence-free survival
T (1, 2, 3, 4): size and extension of tumor (low to high)
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Characteristics of ongoing studies [ordered by study ID]
NCT01224665
Trial name or title A phase III surgical trial to evaluate the benefit of a standard versus an extended pelvic lymphadenectomy
performed at time of radical cystectomy for muscle invasive urothelial cancer
Methods Open-label multicenter randomized parallel study
Participants Estimated enrollment: 620 participants




• Histologically-confirmed urothelial carcinoma of the bladder; Stage T2, T3, or T4a disease; no clinical
stage consistent with a low risk of node metastasis (CIS only, T1); No T4b disease (fixed lesion); disease that
requires primary radical cystectomy and lymph node dissection for definitive treatment; no laparoscopic
surgery
• Predominant urothelial carcinoma with any of the following elements allowed: adenocarcinoma,
squamous cell carcinoma, micropapillary or minor components of other rare phenotype, no pure squamous
cell carcinoma or adenocarcinoma
• No visceral or nodal metastatic disease proximal to the common iliac bifurcation by 2-view chest x-ray
and abdominal-pelvic imaging by computerized tomography or MRI of the abdomen and pelvis
• No intraoperative pelvic lymph node involvement (confirmed by frozen section) at or above the
bifurcation of the common iliac vessels in any of the extended template
Patient characteristics:
• Zubrod performance status 0-2
• ALT and AST ≤ upper limit of normal (ULN)*
• Alkaline phosphatase ≤ ULN*
• Not pregnant or nursing
• Fertile patients must use an effective contraception
• No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ
cervical cancer, or stage I or II cancer from which the patient is in complete remission for the past 5 years
• Medically suitable to undergo cystectomy, in the physician’s opinion
Prior concurrent therapy:
• No prior partial cystectomy for invasive bladder cancer
• No prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g. aorto-femoral/
iliac bypass)
• Prior neoadjuvant chemotherapy for this cancer allowed provided it has been completed and patient
has recovered
• No prior pelvic irradiation
Interventions Intervention
• Patients undergo radical cystectomy and extended pelvic lymphadenectomy
Comparator
• Patients undergo radical cystectomy and standard pelvic lymphadenectomy
Outcomes Primary outcomes
• Disease-free survival (time point measured: 6 years)
Secondary outcomes
• Overall survival (time point measured: 6 years)
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NCT01224665 (Continued)
• Morbidity (time point measured: 6 years)
Starting date August 2011; Expected date of completion: August 2022
Contact information Contact: Jennifer I Scott; jscott@swog.org
Contact: Dana B Sparks, M.A.T; dsparks@swog.org
Notes Funding source: not reported; Sponsors and Collaborators: Southwest Oncology Group; National Cancer
Institute (NCI)
∗Levelsmaybe≥ upper limit of normal (ULN) provided metastatic disease is excluded using dedicated liver imaging, bone scan, or biopsy
ALT :alaninetransaminase
AST: aspartate transaminase
CIS: carcinoma in situ
MRI: magnetic resonance imaging
T (1, 2, 3, 4): size and extension of tumor (low to high)
ULN: upper limit of normal
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D A T A A N D A N A L Y S E S
Comparison 1. Extended versus standard lymph node dissection




participants Statistical method Effect size
1 Time to death from any cause 1 Hazard Ratio (Random, 95% CI) Totals not selected
2 Time to death from bladder
cancer
1 Hazard Ratio (Random, 95% CI) Totals not selected
3 Clavien-Dindo III-V
complications (up to 30 days)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Clavien-Dindo III-V
complications (up to 90 days)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Time to recurrence 1 Hazard Ratio (Random, 95% CI) Totals not selected
6 Clavien-Dindo I-II
complications (up to 30 days)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Clavien-Dindo I-II
complications (up to 90 days)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Extended versus standard lymph node dissection, Outcome 1 Time to death
from any cause.
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection







dissection log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Gschwend 2018 198 203 -0.25 (0.16) 0.78 [ 0.57, 1.07 ]
0.2 0.5 1 2 5
Extended LN dissection Standard LN dissection
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Analysis 1.2. Comparison 1 Extended versus standard lymph node dissection, Outcome 2 Time to death
from bladder cancer.
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection







dissection log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Gschwend 2018 198 203 -0.36 (0.22) 0.70 [ 0.45, 1.07 ]
0.2 0.5 1 2 5
Extended LN dissection Standard LN dissection
Analysis 1.3. Comparison 1 Extended versus standard lymph node dissection, Outcome 3 Clavien-Dindo III-
V complications (up to 30 days).
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection















Gschwend 2018 64/198 58/203 1.13 [ 0.84, 1.52 ]
0.5 0.7 1 1.5 2
Extended LN dissection Standard LN dissection
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Analysis 1.4. Comparison 1 Extended versus standard lymph node dissection, Outcome 4 Clavien-Dindo III-
V complications (up to 90 days).
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection















Gschwend 2018 76/198 64/203 1.22 [ 0.93, 1.59 ]
0.5 0.7 1 1.5 2
Extended LN dissection Standard LN dissection
Analysis 1.5. Comparison 1 Extended versus standard lymph node dissection, Outcome 5 Time to
recurrence.
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection







dissection log [Hazard Ratio] Hazard Ratio Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Gschwend 2018 198 203 -0.17 (0.19) 0.84 [ 0.58, 1.22 ]
0.2 0.5 1 2 5
Extended LN dissection Standard LN dissection
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Analysis 1.6. Comparison 1 Extended versus standard lymph node dissection, Outcome 6 Clavien-Dindo I-II
complications (up to 30 days).
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection















Gschwend 2018 77/198 84/203 0.94 [ 0.74, 1.19 ]
0.5 0.7 1 1.5 2
Extended LN dissection Standard LN dissection
Analysis 1.7. Comparison 1 Extended versus standard lymph node dissection, Outcome 7 Clavien-Dindo I-II
complications (up to 90 days).
Review: Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
Comparison: 1 Extended versus standard lymph node dissection















Gschwend 2018 82/198 92/203 0.91 [ 0.73, 1.14 ]
0.5 0.7 1 1.5 2
Extended LN dissection Standard LN dissection
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A D D I T I O N A L T A B L E S




























































































































203 203 203 190 (93.5)
Total 401 401 401 363 (90.5)
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A P P E N D I C E S
Appendix 1. Search strategies
PubMed (late 1940s-present)
1. “urinary bladder neoplasms”[MeSH Terms] OR bladder neoplasm[tw] OR bladder neoplasms[tw]
2. “carcinoma, transitional cell”[MeSH Terms] OR transitional cell carcinoma[tw] OR transitional cell carcinomas[tw]
3. bladder cancer[tw] OR bladder cancers[tw] OR cancer of the bladder[tw] OR cancers of the bladder[tw] OR bladder tumor[tw] OR
bladder tumors[tw] OR bladder tumor[tiab] OR bladder tumors[tw] OR tumours of the bladder[tw] OR tumors of the bladder[tw]
4. 1 OR 2 OR 3
5. “lymph node excision”[MeSH Terms] OR lymph node excision[tw] OR excision of the lymph node*[tiab] OR lymph node
dissection[tiab] OR dissection of the lymph node*[tw]
6. lymphadenectomy[tw] OR lymphadenectomies[tw]
7. 5 OR 6
8. “cystectomy”[MeSH Terms] OR cystectomy[tw] OR cystectomies[tw]
9. 4 AND 7 AND 8
10. ((((((((randomized controlled trial[pt]) OR controlled clinical trial[pt]) OR randomized[tiab]) OR placebo[tiab]) OR clinical
trials as topic[mesh:noexp]) OR randomly[tiab]) OR trial[ti])) NOT (animals[mh] NOT humans[mh])
11. 9 AND 10
Embase (Elsevier, 1947-present)
(’cystectomy’/exp OR ’cystectomy’ OR ’cystectomies’) AND (’lymph node dissection’/exp OR ’lymph node dissection’ OR ’lymph
node excision’/exp OR ’lymph node excision’ OR ’excision of the lymph node’ OR ’dissection of the lymph node’ OR ’pelvis
lymphadenectomy’/exp OR ’pelvis lymphadenectomy’ OR ’lymphadenectom*’) AND (’bladder cancers’ OR ’bladder cancer’/exp
OR ’bladder cancer’ OR ’bladder carcinoma’/exp OR ’bladder carcinoma’ OR ’bladder carcinomas’ OR ’bladder neoplasm’/exp OR
’bladder neoplasm’ OR ’bladder neoplasms’/exp OR ’bladder neoplasms’ OR ’transitional cell carcinoma’/exp OR ’transitional cell
carcinoma’ OR ’transitional cell carcinomas’ OR ’urothelial bladder cancer’/exp OR ’urothelial bladder cancer’ OR ’urothelial bladder
carcinoma’/exp OR ’urothelial bladder carcinoma’ OR ’bladder tumor’/exp OR ’bladder tumor’) AND [embase]/lim NOT ([embase]/
lim AND [medline]/lim) AND (’crossover procedure’:de OR ’double-blind procedure’:de OR ’randomized controlled trial’:de OR
’single-blind procedure’:de OR random*:de,ab,ti OR factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti)
OR placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:
de,ab,ti OR volunteer*:de,ab,ti)
Cochrane Controlled Trials (Issue 4, April 2019)
#1 MeSH descriptor: [Urinary Bladder Neoplasms] explode all trees
#2 MeSH descriptor: [Carcinoma, Transitional Cell] explode all trees
#3 bladder NEXT cancer:ti,ab,kw OR bladder NEXT cancers:ti,ab,kw OR bladder NEXT tumor*:ti,ab,kw OR bladder NEXT
tumour*:ti,ab,kw OR cancer NEAR/3 of the bladder:ti,ab,kw OR Urothelial NEXT carcinoma*:ti,ab,kw OR transitional NEXT cell
NEXT cancer*:ti,ab,kw
#4 MeSH descriptor: [Lymph Node Excision] explode all trees
#5 excision of the lymph node:ti,ab,kw OR dissection of the lymph node:ti,ab,kw OR lymph node dissection:ti,ab,kw
#6 #1 OR #2 OR #3
#7 #4 OR #5
#8 MeSH descriptor: [Cystectomy] explode all trees
#9 cystectom*:ti,ab,kw
#10 #8 OR #9
#11 #6 AND #7 AND #10
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(Continued)
Web of Science (1900-2019)
1. TS=bladder tumor*
2. TS=urinary bladder neoplasm*
3. TS=bladder cancer*
4. TS=transitional cell carcinoma*
5. TS=cancer of the bladder*
6. TS=urothelial carcinoma*
7. #1 OR #2 OR #3 OR #4 OR #5 or #6
8. TS=lymph node excision*
9. TS=excision of lymph node*
10. TS=lymph node dissection*
11. TS=dissection of the lymph mode*
12. TS=lymphadenedtom*
13. #8 OR #9 OR #10 OR #11 OR #12
14. TS=cystectom*
15. #7 AND #13 AND #14
16. TS=randomized controlled trial*
17. TS=clinical trial*
18. #16 OR #17
19. #15 and #18
LILACS/clinical trials
Bladder cancer AND lymph node resection AND cystectomy
ClinicalTrials.gov
Condition: Bladder cancer
Other Terms: lymph node resection AND cystectomy
World Health Organization (WHO) International Clinical Trials Registry Platform search portal
Bladder cancer AND lymphadenectomy AND cystectomy
Appendix 2. Survey of trial investigators providing information on included trials
Study Date trial author contacted (first) Date trial author provided data (lat-
est)
Data trial author provided
(short summary)
Gschwend 2018 18 Dec 2018 19 Dec 2018 Blinding of outcome assessor
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
This review is based on a registered protocol (PROSPERO; CRD42018116290).
The study included here investigated complication rates 30 and 90 days after the intervention; we have included both results in the
analysis.
N O T E S
We have based parts of the Methods section of this review on a standard template developed by the Cochrane Metabolic and Endocrine
Disorders Group, which has been modified and adapted for use by Cochrane Urology.
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